SLU-PP-332: Dosage, Benefits, FDA Status & Clinics (2026)

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

SLU-PP-332

Where to Buy SLU-PP-332 for Research

Research Use Only — not intended for human consumption

Research peptides are sold for laboratory use only and are not intended for human consumption.

Dosing protocol

Week-by-week dosing, reconstitution steps, supplies checklist, and cycle tips.

Find Clinics Offering SLU-PP-332

1 clinic in our directory offer SLU-PP-332. Use the button below to find one near you.

Denver, CO

Related Peptides

GLP-1 Receptor Agonist

FDA-approved GLP-1 agonist for weight loss and type 2 diabetes.

GIP/GLP-1 Receptor Agonist

Dual GIP/GLP-1 agonist for weight loss and type 2 diabetes.

Synthetic Fragment

Research peptide studied for tissue repair and gut health.

Growth Hormone Releasing Hormone

FDA-approved GHRH analog for growth hormone deficiency.

Continue Reading

Articles about SLU-PP-332 and related topics

SLU-PP-332 Side Effects: What to Know Before Starting Treatment

Explore the side effects of SLU-PP-332, a research compound used in metabolic and mitochondrial studies. Learn about common and serious side effects, and how it compares to similar peptides.

SLU-PP-332 Dosing: What Clinics Prescribe and What to Expect

Explore SLU-PP-332 dosing protocols, titration schedules, and administration methods. Understand the current research landscape for this PPARδ agonist.

SLU-PP-332 Dosage Guide: How Much Should You Take? (2026)

Discover the comprehensive dosing guide for SLU-PP-332, a selective agonist of PPARδ used in metabolic and mitochondrial research.

MyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Key takeaways

SLU-PP-332 activates ERRα and ERRγ receptors, triggering PGC-1α transcription and mitochondrial biogenesis identical to endurance training adaptations.
Research protocols use 25–35mg daily subcutaneous dosing as the optimal range for receptor saturation without exceeding the therapeutic ceiling.
Administration timing 60–90 minutes before fasted metabolic windows produces 34% greater AMPK activation compared to fed-state dosing.
Lyophilized peptide purity ≥98% is required for consistent bioavailability. Impurities below 95% reduce receptor binding and skew metabolic data by 15–20%.
Reconstitution with bacteriostatic water at pH 6.5–7.5 and refrigerated storage at 2–8°C maintains >95% potency for 28 days.
Doses above 50mg do not proportionally increase metabolic outcomes due to ERRα receptor saturation at lower plasma concentrations.

realpeptides.co

SLU-PP-332 + GW501516 Comparison

While structurally different, both SLU-PP-332 and GW501516 target PPARδ receptors, making direct combination inadvisable due to receptor saturation concerns.[2] Comparative research suggest…

Source: mypeptidematch.com

comparison

Comparison of Dosing Protocol Design Strategies

When you're ready to design your own protocol, you're not just picking a number. You're choosing a strategy. Our team has seen labs use several valid approaches, each with its own trade-off…

Source: realpeptides.co

Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching SLU-PP-332 — share findings, ask questions, and learn from real experiences Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement. Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.

Source: peptide-db.com ↗

Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

SLU-PP-332 Dosage, Reconstitution & Mixing Trends

Discover SLU-PP-332 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. SLU-PP-332 is a pan-agonist of the estrogen-related receptor (ERR) family — alpha, beta, and gamma — engineered as an "exercise mimetic" with preclinical rodent work showing improved running endurance, mitochondrial biogenesis, and fat loss without exercise. This data captures the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with SLU-PP-332. 47 SLU-PP-332 reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (15 calculations). The median dose across all sessions is 800mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 5mg (41 sessions). The most common dosing frequency is daily (7x/week) (8 logged protocols), followed by 5x/week (1). World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community. All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.

Source: worldpeptideassociation.com ↗

Potential benefits

Primary Benefits

Powerfully activates ERR receptors to boost mitochondrial function, energy expenditure, and fat oxidation—mimicking the metabolic effects of endurance exercise Induces aerobic exercise genetic programs without physical exertion, increasing oxidative muscle fibers and endurance capacity Reduces fat mass through enhanced metabolism rather than appetite suppression, supporting body composition improvements

Source: peptideinitiative.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →